Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients

Patients with psoriasis are often affected by comorbidities, which largely influence treatment decisions. Here we performed conjoint analysis to assess the impact of comorbidities on preferences of patients with moderate-to-severe psoriasis for outcome (probability of 50% and 90% improvement, time u...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-12, Vol.10 (12), p.e0144335-e0144335
Main Authors: Schaarschmidt, Marthe-Lisa, Kromer, Christian, Herr, Raphael, Schmieder, Astrid, Sonntag, Diana, Goerdt, Sergij, Peitsch, Wiebke K
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antagonists
Anti-Inflammatory Agents - adverse effects
Anti-Inflammatory Agents - therapeutic use
Arthritis
Asthma
Biological Products - adverse effects
Biological Products - therapeutic use
Bronchitis
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - complications
Care and treatment
Cerebral infarction
Comorbidity
Coronary artery
Coronary artery disease
Decision analysis
Dermatologic Agents - adverse effects
Dermatologic Agents - therapeutic use
Diabetes mellitus
Female
Health risk assessment
Health risks
Heart diseases
Humans
Hyperlipidemia
Hypertension
Insulin resistance
Male
Mental depression
Middle Aged
Myocardial infarction
Patient outcomes
Patient Preference
Patient Safety
Patients
Preventive medicine
Psoriasis
Psoriasis - complications
Psoriasis - drug therapy
Psoriatic arthritis
Regression analysis
Risk Factors
Statistical analysis
Sustainability
Variance analysis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with psoriasis are often affected by comorbidities, which largely influence treatment decisions. Here we performed conjoint analysis to assess the impact of comorbidities on preferences of patients with moderate-to-severe psoriasis for outcome (probability of 50% and 90% improvement, time until response, sustainability of success, probability of mild and severe adverse events (AE), probability of ACR 20 response) and process attributes (treatment location, frequency, duration and delivery method) of biologicals. The influence of comorbidities on Relative Importance Scores (RIS) was determined with analysis of variance and multivariate regression. Among the 200 participants completing the study, 22.5% suffered from psoriatic arthritis, 31.5% from arterial hypertension, 15% from cardiovascular disease (myocardial infarction, stroke, coronary artery disease, and/or arterial occlusive disease), 14.5% from diabetes, 11% from hyperlipidemia, 26% from chronic bronchitis or asthma and 12.5% from depression. Participants with psoriatic arthritis attached greater importance to ACR 20 response (RIS = 10.3 vs. 5.0, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0144335